IP Library Granted Patent US 12,102,618
Granted Patent B2
US 12,102,618 · App. 18/353,840 · Granted Oct 1, 2024

Use of riluzole prodrugs to treat ataxias

Inventors: Vladimir Coric (Madison, CT); Robert Berman (New Haven, CT); Melissa Beiner (Madison, CT); Gilbert L'Italien (Deep River, CT)
Assignee: Biohaven Therapeutics Ltd.
A61K31/428A61P25/00A61K9/20A61K9/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,102,618
App. No.
18/353,840
Granted
Oct 1, 2024
Kind
B2
Abstract

Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.

Claims (14)

1. A method of treating spinocerebellar ataxia type 3 in a patient, comprising administering to the patient in need of such treatment a therapeutically effective amount of a riluzole prodrug having the following formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the treatment provides an improvement in the patient's total SARA score of at least 0.8, or 0.9, or 1.0, or 1.1, or 1.2, or 1.3, or 1.4, or 1.5, or 1.6, or 1.7, or 1.8, or 1.9, or 2.0, or greater.

3. The method of claim 1 , wherein the riluzole prodrug is administered to the patient at a dosage of from about 17.5 to 200 mg per day.

4. The method of claim 3 , wherein the riluzole prodrug is administered to the patient at a dosage of about 17.5, or 35, or 70, or 100, or 140, or 200 mg per day.

5. The method of claim 4 , wherein the riluzole prodrug is administered to the patient at a dosage of 200 mg, once per day.

6. The method of claim 4 , wherein the riluzole prodrug is administered to the patient at a dosage of 140 mg, once per day.

7. The method of claim 1 , wherein the riluzole prodrug is administered to the patient once per day.

8. The method of claim 1 , wherein the riluzole prodrug is administered to the patient twice per day.

9. The method of claim 1 , wherein the riluzole prodrug is administered to the patient in the form of a capsule.

10. The method of claim 1 , wherein the riluzole prodrug is administered to the patient in the form of a tablet.

11. The method of claim 1 , wherein the riluzole prodrug is administered to the patient for a duration of from about 8 weeks to 48 weeks.

12. The method of claim 1 , wherein the riluzole prodrug is administered to the patient at a dosage of about 200 mg or less per day.

13. The method of claim 1 , wherein the riluzole prodrug is administered to the patient once daily.

Assignments (1)
SECURITY INTEREST Recorded May 1, 2025
From: BIOHAVEN THERAPEUTICS LTD
To: BEETLEJUICE SA LLC, AS PURCHASER AGENT
Reel/Frame 071147/0260 →
Continuity (4)
Continuation 16762165
Provisional Application 62717948 · Aug 13, 2018
Provisional Application 62584856 · Nov 12, 2017
Related Publication 20230390252A1 · Dec 7, 2023